Drug intelligence / Profile preview

DB-1316

Development stage: Preclinical
Lead developer: Duality Biotherapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

DB-1316 is an antibody-drug conjugate (ADC) currently under development by DualityBio for the treatment of solid tumors. It is the lead candidate utilizing the company's proprietary DUPAC platform. While the specific molecular target and payload details remain undisclosed, the therapeutic is designed to leverage the precision of monoclonal antibodies to deliver a potent cytotoxic agent directly to tumor cells, thereby maximizing anti-tumor activity while limiting systemic exposure. The drug is part of DualityBio's broader pipeline of next-generation ADCs aimed at addressing unmet needs in oncology.

Beyond the preview

Go deeper on DB-1316.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DB-1316.

Explore the full profile